In a phase IIa trial of Pegbelfermin (a PEGylated fibroblast growth factor 21 analogue) treatment in NASH patients, a significant decrease in the plasma level of N-terminal type III collagen propeptide (PRO-C3), a hepatic fibrosis marker that reflects the severity and fibrosis stage, was observed (Sanyal et al., 2019). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.